ProQR Announces Webcast of Presentation at Upcoming HC Wainwright BIOCONNECT Conference
December 18, 2020 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
November 18, 2020 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer
October 05, 2020 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Participate in Upcoming Investor Conferences
September 03, 2020 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Announces Annual Meeting of Shareholders
May 25, 2020 07:00 ET
|
ProQR Therapeutics N.V.
Leiden, Netherlands & Cambridge, Mass., May 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome
March 25, 2020 16:15 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update
February 26, 2020 07:00 ET
|
ProQR Therapeutics N.V.
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal...
ProQR to Present at Upcoming Investor Conferences
November 13, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 06, 2019 07:00 ET
|
ProQR Therapeutics N.V.
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020QR-1123...
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2019 08:20 ET
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of...